Semaglutide is a GLP-1 receptor agonist, a type of medication that mimics the effects of GLP-1
BACKGROUND Obesity disease is an increasing public health challenge in Japan, where it is defined as body mass index (BMI) 25 kg/m and is associated with a substantial burden of obesity-related comorbidities, including type 2 diabetes (T2D), cardiovascular disease (CVD), and impaired quality of life
Any drug in this class could potentially carry this risk
Semaglutide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying
By choosing Semaglutide, you receive a tailored formula created to meet your specific health needs, ensuring a personalized approach to achieving long-term results
Use the tables above as a guide to the conversation with your prescriber, start conservatively, and give the new medication a few weeks at a stable dose before judging it